Healthcare / Drug Manufacturers - Specialty & GenericStockholm
$19.64
-0.46 (-2.29%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-195.4M · quality 46.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
30/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$690M
P/E
N/A
•EV/EBITDA
N/A
•ROE
130.3%
↑Gross Margin
44.2%
↓Debt/Equity
1.00
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-65.3%
FCF CAGR
—
FCF margin
-751.5%
FCF / Net income
-0.31x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $26.0M · net income $639.3M · FCF $-195.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $26.0M | $26.0M | $29.7M | $638.8M | $624.3M |
| Net Income | $639.3M | $639.3M | $-203.0M | $-128.3M | $-177.6M |
| EBITDA | $-285.7M | $-285.7M | $-252.4M | $-22.0M | $-73.9M |
| EPS | -11.65 | -11.65 | -13.86 | -3.73 | -5.17 |
| Gross Margin | 44.2% | 44.2% | 37.0% | 86.1% | 83.6% |
| Operating Margin | -1310.0% | -1310.0% | -1457.9% | -17.0% | -34.3% |
| Net Margin | 2458.8% | 2458.8% | -683.5% | -20.1% | -28.4% |
| Balance Sheet | |||||
| Debt/Equity | 1.00 | 1.00 | -3.77 | 8.04 | 2.78 |
| Current Ratio | 2.02 | 2.02 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-195.4M | $-195.4M | $-331.2M | $-114.2M | $-180.5M |
| Returns | |||||
| ROE | 130.3% | 130.3% | 160.7% | -217.8% | -91.6% |
| Valuation | |||||
| P/B | 1.58 | 1.58 | — | 8.95 | 3.34 |
| Growth & Yield | |||||
| Revenue Growth | -12.5% | -12.5% | -95.4% | 2.3% | — |
| EPS Growth | 15.9% | 15.9% | -271.6% | 27.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+33.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-13.86 → -11.65
Residual
+33.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.